Postoperative aRCH With Cisplatin Versus aRCH With Cisplatin and Pembrolizumab in Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT03480672 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

211

Enrollment

OTHER

Sponsor class

Conditions

HNSCC

Interventions

DRUG: Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
OTHER: adjuvant radiochemotherapy

Sponsor

University of Leipzig